GEORGE CHOLANKERIL to Cohort Studies
This is a "connection" page, showing publications GEORGE CHOLANKERIL has written about Cohort Studies.
Connection Strength
0.207
-
Reply to: "Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea". J Hepatol. 2024 May; 80(5):e218-e219.
Score: 0.093
-
Estimated pulse wave velocity in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality. J Gastroenterol Hepatol. 2024 Sep; 39(9):1950-1956.
Score: 0.024
-
Exposure to Agent Orange and Hepatocellular Carcinoma Among US Military Personnel. JAMA Netw Open. 2023 12 01; 6(12):e2346380.
Score: 0.023
-
The impact of chronic liver disease in patients receiving active pharmacological therapy for opioid use disorder: One-year findings from a prospective cohort study. Drug Alcohol Depend. 2020 04 01; 209:107917.
Score: 0.018
-
Diet quality and its association with nonalcoholic fatty liver disease and all-cause and cause-specific mortality. Liver Int. 2020 04; 40(4):815-824.
Score: 0.018
-
Readmission Rates and Associated Outcomes for Alcoholic Hepatitis: A Nationwide Cohort Study. Dig Dis Sci. 2020 04; 65(4):990-1002.
Score: 0.017
-
Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States. Hepatology. 2017 07; 66(1):46-56.
Score: 0.015